NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS)
Stock · NASDAQ · Health Care
$19.83as of 10/16/2026
Price chart
Active signals
NAMS Signal Track Record
How signals performed across all stocks →What NAMS's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 43 | -0.9% | 49% | September 17, 2026 |
| Bollinger Band Breakout | 27 | -0.9% | 41% | June 29, 2026 |
| Bollinger Band Breakdown | 23 | +5.3% | 61% | August 28, 2026 |
| 200-Day Moving Average TouchActive now | 21 | +1.6% | 71% | June 26, 2026 |
| Any 20-session window (baseline) | +0.3% | 55% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About NAMS
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 100
- Website
- ir.newamsterdampharma.com/
Fundamentals
- 1-day range
- $20.04$21.34
- Market cap
- $3.23B
- P/E (trailing)
- —
- P/E (forward)
- -13.16
- EPS (trailing)
- $-2.15
- Dividend yield
- —
- Beta
- 0.09
- Avg. volume
- 1.37M
How NewAmsterdam Pharma Company N.V. Ordinary Shares Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 18, 2026 · via SEC EDGAR / Finnhub
Forecasts
15 analyst ratings
NewAmsterdam Pharma Company N.V. Ordinary Shares Competitors
Chosen by industry and closest market cap.
- NAMSNewAmsterdam Pharma Company N.V. Ordinary Shares$19.83▼ 3.83%Market cap $3.23BP/E —$20.91$42.21
- MBXMBX Biosciences Inc. Common Stock$49.61▼ 2.17%Market cap $3.19BP/E —$12.94$72.64
- ARQTArcutis Biotherapeutics Inc. Common Stock$28.82▼ 0.96%Market cap $3.31BP/E 128.52$19.3$31.77
- QUREuniQure N.V. Ordinary Shares$21.78▼ 3.29%Market cap $3.15BP/E —$8.73$71.5
- IRONDisc Medicine Inc. Common Stock$56.84▲ 0.34%Market cap $2.97BP/E —$40$99.5
- IDYAIDEAYA Biosciences Inc. Common Stock$32.85▼ 2.95%Market cap $3.50BP/E —$26.44$42.68
- ALMSAlumis Inc. Common Stock$6.12▼ 3.01%Market cap $3.54BP/E —$4.37$31.35
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| NAMS NewAmsterdam Pharma Company N.V. Ordinary Shares | $3.23B | — | $19.83 | ▼ 3.83% | $20.91$42.21 |
| MBX MBX Biosciences Inc. Common Stock | $3.19B | — | $49.61 | ▼ 2.17% | $12.94$72.64 |
| ARQT Arcutis Biotherapeutics Inc. Common Stock | $3.31B | 128.52 | $28.82 | ▼ 0.96% | $19.3$31.77 |
| QURE uniQure N.V. Ordinary Shares | $3.15B | — | $21.78 | ▼ 3.29% | $8.73$71.5 |
| IRON Disc Medicine Inc. Common Stock | $2.97B | — | $56.84 | ▲ 0.34% | $40$99.5 |
| IDYA IDEAYA Biosciences Inc. Common Stock | $3.50B | — | $32.85 | ▼ 2.95% | $26.44$42.68 |
| ALMS Alumis Inc. Common Stock | $3.54B | — | $6.12 | ▼ 3.01% | $4.37$31.35 |
P/E shows — for peers not currently carrying a live signal of their own.
Insider Activity
Insider Actions →- Johannes Jacob Pieter Kastelein · August 24, 2026 · Option Exercise125.0K
- Johannes Jacob Pieter Kastelein · August 24, 2026 · Sale125.0K @ $26.91
- Louise Frederika Kooij · July 20, 2026 · Option Exercise80.0K @ $11.17
- Louise Frederika Kooij · July 20, 2026 · Option Exercise25.0K @ $11.9
- Louise Frederika Kooij · July 20, 2026 · Sale2.9K @ $31.71
- Louise Frederika Kooij · July 20, 2026 · Sale31.9K @ $31.05
- Louise Frederika Kooij · July 20, 2026 · Sale70.2K @ $29.96
- Louise Frederika Kooij · June 22, 2026 · Option Exercise15.0K @ $11.9
- Louise Frederika Kooij · June 22, 2026 · Option Exercise25.0K @ $10.9
- Louise Frederika Kooij · June 22, 2026 · Sale300 @ $30.73
- Louise Frederika Kooij · June 22, 2026 · Sale39.7K @ $30.2
- Louise Frederika Kooij · May 26, 2026 · Option Exercise5.0K @ $10.9
- Louise Frederika Kooij · May 26, 2026 · Option Exercise60.0K @ $10
- Louise Frederika Kooij · May 26, 2026 · Sale65.0K @ $35.69
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
RBC Capital Lowers Target to $42 for NAMS
RBC Capital has kept its outperform rating for NewAmsterdam Pharma (NAMS) but cut its price target to $42. The new target sits at the top of the 52‑week range and near the current support level of $35.04. The stock’s RSI of 33.5 suggests it is in an oversold zone, which may influence short‑term trading activity. Analysts still see upside potential, but the lowered target reflects a more cautious outlook.
RBC Capital Lowers Target to $42 for NAMS. RBC Capital has kept its outperform rating for NewAmsterdam Pharma (NAMS) but cut its price target to $42. The new target sits at the top of the 52‑week range and near the current support level of $35.04. The stock’s RSI of 33.5 suggests it is in an oversold zone, which may influence short‑term trading activity. Analysts still see upside potential, but the lowered target reflects a more cautious outlook.